Mana.bio, a Tel Aviv, Israel-based biotechnology company working on programmable drug delivery, has raised $19.5 million in a seed financing round.
SaaS Investors
The seed financing round was co-led by Andreessen Horowitz Bio + Health, Base4 Capital, NFX, Technion, and LionBird.
Andreessen Horowitz Bio + Health invests in tech-forward healthcare entrepreneurs and innovators who are leading the way in biological engineering.
Base4 Capital is an investment firm.
NFX is a venture capital firm investing in pre-seed and seed-stage startups. The firm backs exceptional founders building market-transforming companies.
Technion – Israel Institute of Technology is a public research university in Haifa, Israel.
LionBird invests in early-stage technology startups that improve offline processes in healthcare, commerce, and enterprise. The firm is based in Tel Aviv, Israel, and has an additional office in Evanston, Illinois
Mana.bio Use of Funds
The company plans to use the financing to advance the development of its proprietary, purpose-built AI LNP platform.
About Mana.bio
Mana.bio is an AI-based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines. Mana.bio's platform leverages artificial intelligence to design and optimize LNPs for safe and tissue-specific delivery of RNA payloads. The company is on a mission to disrupt the drug delivery space using combined forces of machine learning and nanotechnology.
Funding Details
Company: Mana Bio Ltd.
Raised: $19.5
Round: Seed Round
Funding Month: October 2023
Lead Investors: Andreessen Horowitz Bio + Health, Base4 Capital, NFX, Technion, and LionBird
Additional Investors:
Company Website: https://www.mana.bio/
Software Category: AI-based Drug Delivery
Source: https://www.prnewswire.com/news-releases/manabio-advances-ai-based-lipid-nanoparticle-lnp-platform-to-accelerate-programmable-drug-delivery-for-rna-and-gene-therapies-301952340.html